

Senior finance executive with 20+ years of experience leading finance, M&A, and enterprise transformation across global pharmaceutical, life sciences, and industrial organisations. Track record across PE-backed and publicly listed companies across the US, Japan, and other international markets, with P&L responsibility up to \$1B, multi-country operations across EMEA, Americas, and APAC, and leadership of teams up to 60+. Trusted board-level partner supporting CEOs, investors, and senior leadership teams on value creation, capital allocation, risk management, and strategic decision-making.

SELECTED VALUE CREATION, TRANSFORMATION & TRANSACTIONS

- **Takeda-Shire integration.** Led finance integration across 11 countries following a major global pharma merger. Unified reporting, controls, and performance management within two months. Delivered post-merger synergies including approximately 15 percent payroll savings and over 25 percent operating expense reduction.
- **Merz Pharma transformation.** Country CFO-level leadership of end-to-end financial and operating model transformation for a regional pharma business. Designed and implemented a 10-year financial model. Delivered approximately \$3M annual tax savings and a 30-day working capital improvement.
- **Buy-side M&A.** Led a \$400M buy-side acquisition at Takeda prior to the Shire merger. Owned valuation, financial modelling, and transaction analysis supporting investment and integration decisions.
- **JV renegotiation post-merger.** Led financial modelling and commercial negotiations for a joint venture inherited through the Shire acquisition. Improved deal economics by \$30M through revised structure and commercial terms.
- **PE exit preparation.** Led full sell-side readiness for a PE-backed pharmaceutical business including data room preparation, financial modelling, equity story development, and management presentations to potential buyers. Capital projects.

PROFESSIONAL EXPERIENCE

Thermo Fisher Scientific · Global Finance Director

2025-02 to present

- Finance lead and strategic partner for global operations generating \$700M revenue across EMEA, Americas, and APAC.
- Own performance management, analytics, and strategic finance processes supporting pricing, portfolio, and investment decisions.
- Lead finance transformation agenda including automation, AI-enabled analytics, and operating model improvements.
- Advise divisional leadership on financial implications of growth initiatives, restructuring, and M&A opportunities.

IQVIA Laboratories · Global Business Finance Director

2023-05 to 2025-01

- Owned global FP&A, commercial finance, and performance management for approximately \$1B revenue business across three regions.
- Strategic finance partner to senior executives and co-presenter at corporate performance and strategy reviews.
- Designed and implemented commercial deal controls and pricing governance delivering immediate margin improvement.
- Standardised global budgeting, forecasting, and KPI frameworks improving comparability and executive visibility.
- Built and led diverse, multi-region finance teams supporting growth and operational scale.

Arrival (listed EV scale up) · Divisional Finance Director

2021-05 to 2023-04

- Finance lead for UK and US entities with responsibility for IFRS reporting, SOX controls, audit, cash flow, and working capital.
- Business partner to founders and board on manufacturing scale-up, pricing strategy, funding options, and capital allocation.
- Led development of a five-year integrated financial and operational model for EV production.
- Implemented approximately \$400M CAPEX tracking and cash forecasting tools supporting capital discipline and board reporting.
- Led preparation of government financing applications and engagement with public stakeholders.

Takeda Pharmaceuticals · Regional Finance Director

2017-12 to 2021-02

- Regional CFO-equivalent role overseeing finance for 11 countries with approximately \$600M revenue and teams of 60+.
- Accountable for FP&A, accounting, treasury, tax, internal controls, compliance, and enterprise risk management.
- Led finance integration following the Takeda-Shire merger, unifying reporting, governance, and performance management.
- Led finance workstream on a \$400M buy-side acquisition prior to the Shire merger.
- Led financial modelling and negotiations for post-merger JV restructuring, improving deal value by \$30M.
- Reduced budget cycle time by approximately 30 percent through process redesign and automation.

Petrovax Pharmaceuticals · CFO

2017-04 to 2017-11

- Full-cycle CFO reporting to private equity sponsors and the board.
- Oversaw accounting, FP&A, treasury, tax, ERP, and IT infrastructure with a team of 30+.
- Led full exit preparation including data room build, financial models, equity story, and management presentations to potential buyers.
- Personally pitched management presentation to prospective acquirers and advisors.
- Exit process completed end-to-end without transaction close.

Merz Pharma GmbH · Regional Finance Director

2015-09 to 2017-03

- Country CFO with full accountability for regional finance including P&L, treasury, tax, compliance, and governance.
- Led a multi-year finance and operating model transformation programme aligned with group strategy.
- Developed a 10-year financial model supporting structural change and long-term capital planning.
- Delivered approximately \$3M annual tax savings and a 30-day working capital improvement.
- Led SAP redesign and transfer pricing changes to support the new operating model and compliance requirements.

EDUCATION

Chartered Institute of Management Accountants, CIMA member (ACMA, CGMA)	06-2015 to 06-2019
INSEAD Business School, Singapore, Strategy and Disruption in Digital Era	11-2019 to 11-2019
Saint-Petersburg State University, MSc in finance and management	06-2000 to 06-2005

CONTACT

Web: <https://www.maksim-dementev.com/>

Email: contact@maksim-dementev.com

LinkedIn: www.linkedin.com/in/maksim-dementev

Phone: +447507530594